Collaboration and co-marketing agreement with QIAGEN to advance CTC–based research with its pharmaceutical partners

1. Joint promotion of the Parsortix platform and QIAGEN’s molecular technologies
2. Opportunity for the development of a companion diagnostic assay

Guildford, UK, –  18 November 2025 – CELLBXHEALTH plc (AIM: CLBX; OTCQX: ANPCY), a global leader in circulating tumour cell (CTC) intelligence, announces that it has entered into a non-exclusive Collaboration and Co-Marketing Agreement with QIAGEN Manchester Ltd., a UK-based subsidiary of QIAGEN N.V. (NYSE: QGEN; Frankfurt: QIA), a global provider of sample and assay technologies for molecular diagnostics and life sciences.

The agreement enables QIAGEN to offer the Parsortix platform to its pharmaceutical partners as part of collaborative projects combining CTC enrichment and analysis with QIAGEN’s PCR, digital PCR, and NGS workflows. These projects are expected to support drug development programmes, biomarker discovery, and early-stage companion diagnostic feasibility studies.  

Partnering with a global provider of assay technologies for molecular diagnostics, is illustrative of the Company’s key focus in driving commercial progress.

Under the agreement, QIAGEN may contract directly with pharmaceutical partners, outsourcing exploratory CTC projects to CellBxHealth. The projects will integrate the Parsortix platform with QIAGEN’s molecular analysis tools to provide deeper insights into tumour biology and therapeutic response.

Key terms of the collaboration include:

1. Joint promotion of the Parsortix platform and QIAGEN’s molecular technologies to pharmaceutical and biotechnology partners
2. Establishment of laboratory services projects in which QIAGEN serves as the contracting party with pharma partners, with project execution subcontracted to CellBxHealth
3. Commitment to explore integration of QIAGEN’s technologies, including NGS and automated DNA extraction systems, within the Parsortix workflow
4. Opportunity for the development of a companion diagnostic assay or similar product incorporating both companies’ technologies

CTCs provide a real-time, non-invasive means of accessing tumour material from patient blood, enabling molecular analysis of tumour evolution, therapeutic targets, and resistance mechanisms. Integrating CellBxHealth’s CTC technology with QIAGEN’s leading molecular tools is expected to accelerate the adoption of liquid biopsy–based approaches in oncology drug development and companion diagnostics.

Peter Collins, Chief Executive Officer of CelLBxHealth, said: "This agreement marks an important step in extending the commercial and scientific reach of our Parsortix platform through collaboration with QIAGEN, a global leader in molecular diagnostics. By combining our technologies, we can offer pharmaceutical partners a comprehensive solution for CTC-based analysis — spanning enrichment, molecular characterization, and diagnostic development. This collaboration aligns with our strategy to broaden access to our CTC technology and expand its role in precision medicine as we focus on multiple commercial opportunities."